Scarica l'app Stockscreener
0.00
100.00%
-1.71
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché APTO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.71
Aprire:
$0
Volume 24 ore:
0
Relative Volume:
0.00
Capitalizzazione di mercato:
$10.59M
Reddito:
-
Utile/perdita netta:
$-35.80M
Rapporto P/E:
0.00
EPS:
-2.97
Flusso di cassa netto:
$-37.18M
1 W Prestazione:
-100.00%
1M Prestazione:
-100.00%
6M Prestazione:
-100.00%
1 anno Prestazione:
-100.00%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$0.00
$0.00
Portata 52W:
$0.00
$14.28
Aptose Biosciences Inc Stock (APTO) Company Profile
Nome
Aptose Biosciences Inc
Settore
Industria
Telefono
310-849-8060
Indirizzo
66 WELLINGTON STREET WEST, SUITE 5300, TORONTO, ON
Confronta APTO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APTO
Aptose Biosciences Inc
|
0.00 | 10.59M | 0 | -35.80M | -37.18M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.72B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.50 | 60.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 58.15B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 41.45B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Aptose Biosciences Inc Stock (APTO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-10-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-09-22 | Iniziato | Alliance Global Partners | Buy |
| 2020-02-20 | Iniziato | Maxim Group | Buy |
| 2020-02-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-01-09 | Iniziato | Piper Sandler | Overweight |
| 2019-03-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-16 | Iniziato | B. Riley FBR | Buy |
| 2017-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2017-10-23 | Ripresa | ROTH Capital | Buy |
| 2017-09-07 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2017-06-08 | Iniziato | Rodman & Renshaw | Neutral |
Mostra tutto
Aptose Biosciences Inc Borsa (APTO) Ultime notizie
Aptose Biosciences Secures Funding for Drug Development - MSN
Aptose Biosciences Reports Promising Results from TUSCANY Trial in AML - MSN
Aptose Biosciences Appoints New Independent Auditor - TipRanks
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor - MarketScreener
Aptose Biosciences Reports Positive Early Data from TUSCANY Trial for AML Treatment - TipRanks
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial - Yahoo Finance
Aptose Biosciences Advances Tuspetinib in AML Treatment with Promising Trial Results - MSN
Aptose Biosciences: Q2 Earnings Snapshot - Greenwich Time
Aptose Biosciences Inc. SEC 10-Q Report - TradingView
Aptose Reports Second Quarter 2025 Results - The Manila Times
When (APS) Moves Investors should Listen (APS:CA) - news.stocktradersdaily.com
Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy - The Manila Times
Aptose Biosciences Advances TUSCANY Trial with Dose Escalation - TipRanks
Aptose Cancer Drug Tuspetinib Advances to 160mg Dose After Successful Trial Results | APTOF Stock News - Stock Titan
(APS) Financial Trading Report (APS:CA) - news.stocktradersdaily.com
Where are the Opportunities in (APS) (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Appoints Ernst & Young as New Auditor - The Globe and Mail
Aptose Selects Ernst & Young Global Limited as its New Independe - GuruFocus
Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders - The Manila Times
(APS) Equity Trading Insights (APS:CA) - news.stocktradersdaily.com
Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML - The Manila Times
About Us - FinancialContent
(APS) Comprehensive Trading Strategy Report (APS:CA) - news.stocktradersdaily.com
Delisting of Securities from The Nasdaq Stock Market - The Globe and Mail
(APS) Technical Patterns and Signals (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Upgrades to OTCQB Market Listing - TipRanks
Aptose Announces Deferral of Interest Payment | APTOF Stock News - GuruFocus
Aptose Biosciences Defers Loan Interest Payments to Enhance Financial Flexibility - TipRanks
Aptose Biosciences Secures $8.5M Loan Agreement - TipRanks
(APS) Investment Performance Report (APS:CA) - news.stocktradersdaily.com
(APS) Equity Market Report (APS:CA) - news.stocktradersdaily.com
Aptose and Hanmi Enter New Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML - Yahoo Finance
Stocks In Play: Aptose Biosciences Inc. - Barchart.com
Aptose Provides Corporate Updates - The Manila Times
Aptose Provides Corporate Updates | APTOF Stock News - GuruFocus
Aptose CEO props up biotech's finances to prevent company from going bust - Fierce Biotech
(APS) Investment Analysis and Advice (APS:CA) - news.stocktradersdaily.com
Aptose Presents Safety, Response, and MRD Clinical Data from TUS - GuruFocus
Aptose reports promising data from TUS+VEN+AZA therapy for AML By Investing.com - Investing.com South Africa
Aptose reports promising data from TUS+VEN+AZA therapy for AML - Investing.com Canada
Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2025 EHA Congress - The Manila Times
APTOAptose Announces Reverse Share Split - Revista ADVFN
(APS) Technical Pivots with Risk Controls (APS:CA) - news.stocktradersdaily.com
Aptose Biosciences Inc Azioni (APTO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
8.06%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):